Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium selenate in behavioural variant frontotemporal dementia
ACTRN12617001218381Phase 2Terminated
- Sponsor
- Melbourne Health
- Start
- Aug 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sodium selenate in behavioral variant frontotemporal dementia (bvFTD), sponsored by Melbourne Health. Primary endpoint: Safety and tolerability of sodium selenate. Started Aug 2017; status: terminated.
02
Drugs
sodium selenate
03
Conditions
behavioral variant frontotemporal dementia (bvFTD)
Beyond the preview
Go deeper on ACTRN12617001218381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001218381.